Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

European Society For Medical Oncology

ESMO-TAT-2025-1000x250-Register-Now
Early Reg deadline: 15 January
Early Reg deadline: 15 January

ESMO Targeted Anticancer Therapies Congress 2025

Gain insights into the future of cancer drug development: ESMO TAT represents an excellent opportunity to stay up to date with the latest early phase trials in oncology while learning multi-stakeholder perspectives

Register now and save
ESMO-AI-and-Digital-Oncology-2025-1000x250
ESMO AI & Digital Oncology Congress 2025
ESMO AI & Digital Oncology Congress 2025

Save the date!

A pioneering forum dedicated to the intersection of AI, digital health and oncology

Find out more
ESMO-MCBS 1000x1000

ESMO-MCBS

A validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.

Discover more

Latest News

More Oncology News More Press Releases More Society Updates Read the ESMO Daily Reporter
More Oncology News
Press Releases Event Announcement

ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December

The ESMO Immuno-Oncology Congress 2024 will take place in Geneva, Switzerland, from December 11-13, with an option to attend virtually. Leading experts will present and discuss the research advancements in the rapidly evolving field of immuno-oncology

Press Releases Event Announcement

Molecular Analysis for Precision Oncology Congress 2024 London, UK, 16-18 October

The Molecular Analysis for Precision Oncology Congress 2024 (MAP) is the appointment where globally recognised experts will present and discuss research in precision medicine, technologies for cancer profiling, mechanisms driving tumour expansion, metastatic dissemination, clonal evolution, and biomarker-driven development of targeted therapeutics

Press Releases ESMO Congress 2024 Press Release

Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group of Women with Early-Stage Disease

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found ‘promising’ antitumour activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers

Press Releases ESMO Congress 2024 Press Release

From Practice-Changing Data to Future Innovation, Patient Outcomes to Doctors’ Wellbeing, the ESMO Congress 2024 Takes a Holistic View of Oncology

The ESMO Congress 2024 taking place 13-17 September in Barcelona, Spain, offers a comprehensive view of the current drug development landscape, with existing medicines demonstrating benefit in additional applications and new agents emerging in large numbers as the range of potential molecular targets for therapy continues to expand

Press Releases Media Alert

ESMO 2024 Press Conference

The ESMO Congress 2024 will hold a press conference to introduce and discuss the “Eyes to the Future” Presidential Symposium 3, that will be presenting prominent approaches that have the potential to become increasingly effective and influential components of cancer treatment in the (near) future.

Press Releases ESMO Congress 2024 Press Release

Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe

According to two international studies presented at the ESMO Congress 2024, women who breastfeed after receiving treatment for breast cancer, including those with a germline BRCA mutation (an inherited change in BRCA genes that significantly increases the risk of developing certain cancers, especially breast cancer), do not face an increased risk of recurrence or developing new breast cancers

More Press Releases
Society Updates Society Updates

ESMO Award for Immuno-Oncology 2024 Recipient Announced

The ESMO Award for Immuno-Oncology 2024 is presented to Ton N. Schumacher in recognition of his exceptional contributions to cancer immunology and to our understanding of the mechanism of how immunotherapy works

Society Updates

ESMO Congress 2024: Five Days of Science Dissemination and Education

Bringing another annual reunion of the global oncology community to a resounding close, the 34,000 attendees of the ESMO Congress 2024 had the opportunity to gather around to listen to the most important results presented in different tumour types and research areas

Society Updates Society Updates

New ESMO President 2027-2028 Elected

ESMO has announced today the results of its Presidential elections following the closure of the voting system on Monday, 10 June 2024.

More Society Updates
Daily Reporter

Are we close to personalise immunotherapy?

According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field

Read the ESMO Daily Reporter

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.